Pangaea Data

What Pangaea Data does

Pangaea Data is a London- and San Francisco-headquartered AI software company founded in 2017 that builds the PALLUX platform, a multimodal AI system designed to analyze structured and unstructured patient data — including clinical records, imaging, genomic information, and real-world data — to identify individuals who are undiagnosed, under-treated, or at elevated clinical risk. The company's core application is surfacing patients with conditions where diagnostic delays are long and underdiagnosis is severe, with the lead use case being Alpha-1 Antitrypsin Deficiency (AATD), where it claims up to 90% of U.S. patients remain undiagnosed despite relevant information already existing in medical records. The platform has expanded into adjacent therapeutic areas including COPD, severe asthma, rare disorders, ophthalmology (glaucoma and diabetic retinopathy via integration with Topcon's Harmony platform), and oncology social drivers of health.

The company operates an enterprise go-to-market in which large pharmaceutical companies and healthcare technology vendors sponsor the configuration and deployment of the platform. Strategic multi-year partnerships with Sanofi (AATD deployment across select U.S. health systems and low-income community clinics) and AstraZeneca (global multimodal AI deployment for clinical decision-making, patient identification, and clinical trial recruitment) anchor the commercial model. Additional relationships include a strategic investment and platform integration from Topcon Healthcare and an academic deployment at the University of Illinois Chicago Cancer Center. Pangaea leverages generative and predictive AI capabilities from Microsoft and NVIDIA rather than positioning itself as a foundation model developer.

The business model is enterprise platform licensing via multi-year, sponsor-funded deployments with undisclosed contract values and custom configuration terms. The company is privately held and venture-backed, with disclosed institutional investors including Ascension, Salica, IQ Capital, and Koa Labs (2021 round), alongside a 2025 strategic investment from Topcon Healthcare. With 11-50 employees, Pangaea is an early-stage, commercially scaling company rather than a mature enterprise software vendor, and its revenue, headcount growth rate, and customer count beyond named logos are not publicly disclosed.

Name

Pangaea Data

Legal name

Pangaea Data

Website

https://pangaeadata.ai

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Healthcare AI Software

NAICS

Software Publishers (5132)

SIC

Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF)

akta.pro secondary industry

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

Keywords

• Clinical decision support
• Healthcare AI platform
• Patient identification software
• Multimodal medical AI
• Rare disease diagnostics

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Enterprise Platform Licensing and Deployment: Multi-year enterprise agreements with pharmaceutical companies and healthcare systems where partners sponsor configuration and deployment of Pangaea's AI platform

Go-to-market motion2 records

Distribution channels3 records

Core offering

Pangaea Data provides the PALLUX platform, a proprietary AI-driven software that analyzes structured and unstructured patient records in real-time to identify underdiagnosed and untreated patients. The platform integrates clinical, imaging, genomic, and real-world data through multimodal AI capabilities (leveraging Microsoft and NVIDIA technologies) to support clinical decision-making for patient identification, diagnosis, treatment, and connection to therapies or clinical trials across conditions including genetic disorders, respiratory diseases, cancer, and eye health.

Product overview

Pangaea Data offers a unified AI platform for population health management and clinical decision support. The core product, PALLUX, is a proprietary AI platform that analyzes structured and unstructured patient data to identify at-risk individuals, supporting early detection of underdiagnosed conditions. The platform integrates clinical, imaging, genomic, and real-world data to enable multimodal AI capabilities for improving patient identification, diagnosis, and connection to appropriate treatments or clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

• PALLUX Platform Proprietary AI platform that analyzes structured and unstructured patient records to identify untreated and underdiagnosed patients in real-time, supporting disease detection across multiple therapeutic areas including genetic disorders (e.g., AATD), respiratory conditions (COPD, severe asthma), cancer (SDOH analysis), and eye health (glaucoma, diabetic retinopathy). Designed for pharmaceutical companies, healthcare systems, academic medical centers, and ophthalmology providers.

Quantifiable outcome

• Up to 90% of people with AATD remain undiagnosed in the U.S.
• +1 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability7 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• SanoficoreStrategic or Co-development Partner · 22 June 2026Partnership with Sanofi to deploy an AI platform for detecting Alpha-1 Antitrypsin Deficiency (AATD), a genetic disorder affecting the lungs and liver. The platform will be distributed across select U.S. healthcare systems and low-income community clinics to identify at-risk individuals in real-time.
• AstraZenecacoreStrategic or Co-development Partner · 5 December 2025Strategic multi-year partnership with AstraZeneca to deploy multimodal AI in clinical settings. AstraZeneca is sponsoring the configuration and deployment of Pangaea's enterprise platform that integrates clinical, imaging, genomic, and real-world data. The collaboration leverages generative and predictive AI capabilities from Microsoft and NVIDIA to scale AI-driven clinical decision-making for patient identification, diagnosis, treatment, and connection to therapies or clinical trials.
• University of Illinois Chicago Cancer CenterminorStrategic or Co-development Partner · 11 November 2025Pangaea Data's AI platform was adopted by the University of Illinois Chicago Cancer Center to analyze electronic health records and uncover social drivers of health (SDOH) impacting patient outcomes in urologic cancer patients.
• Topcon HealthcarecoreStrategic or Co-development Partner · 1 May 2025Topcon Healthcare's strategic investment in Pangaea Data's AI platform PALLUX, marking the company's second investment in less than a week as part of its Healthcare from the Eye initiative. The PALLUX platform analyzes patient records to identify untreated and under-treated patients.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Tempus AI: AI-driven precision medicine platform that integrates clinical, molecular, and imaging data with pharma partnerships for patient identification and clinical trial recruitment. Closely aligned with Pangaea's multimodal data and pharma-sponsorship model.
• Owkin: AI-for-clinical-research platform with deep pharma partnerships, focused on patient stratification and real-world data analytics. Highly comparable go-to-market and technology stack to Pangaea.
• nference: AI/biomedical informatics platform that derives insights from structured and unstructured clinical data and partners with pharma. Directly comparable multimodal EHR-to-pharma offering.

Broad incumbents

• IQVIA: Largest real-world data and clinical decision support vendor, serving pharma and providers globally. Indirect competitor given breadth, with overlap in RWD-driven patient identification.
• Verily (Alphabet): Clinical data, real-world evidence, and AI-driven care platforms within Alphabet. Comparable multimodal clinical-to-pharma model at greater scale and capital depth.
• Foundation Medicine: Molecular diagnostics and genomic profiling company (Roche) used by pharma for patient identification and clinical trials. Comparable genomics-driven pharma partnership model.
• Flatiron Health: Oncology-focused EHR data and analytics platform (Roche), serving pharma for patient identification and RWD. Comparable in pharma-served real-world clinical data analytics.

Emerging players

• ConcertAI: AI-driven real-world evidence and clinical decision support for oncology, with pharma-sponsored deployments. Comparable in targeting pharma customer base and RWD analytics.
• Arterys: Cloud-native AI medical imaging platform integrated into clinical workflows. Adjacent to Pangaea's imaging-modality capability and clinical decision support positioning.
• DeepHealth (RadNet): AI-powered clinical imaging and workflow platform, with pharma and provider partnerships. Comparable in combining imaging with clinical decision support.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/pangaeadataai

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pangaea Data